Engitix has appointed Ryan Richardson as an Independent Non-Executive Director as the biotechnology company advances its proprietary pipeline toward clinical development and expands its platform and partnership strategy.
The London-based company is developing extracellular matrix-based drug discovery and development programs across oncology, fibrosis, and fibro-inflammatory diseases. Its platform combines a patient-derived extracellular matrix bioarchive with multimodal disease datasets, advanced human 3D models, and AI and machine learning analytics to identify disease mechanisms, therapeutic targets, and biomarkers.
Richardson is Founder and CEO of Bios Life and brings experience spanning biotechnology, oncology, artificial intelligence, capital markets, fundraising, and corporate development.
Previously, he spent seven years as Chief Strategy Officer and an Executive Board Member at BioNTech. During his tenure, Richardson helped lead the company through its Series B financing, Nasdaq IPO, and subsequent public financings that raised more than $1 billion in equity capital.
He was also involved in BioNTech’s international expansion, corporate strategy, and oncology portfolio as the company developed from a privately held clinical-stage biotechnology business into a global public company. Richardson later served as Chairman of InstaDeep following its acquisition by BioNTech, adding experience at the intersection of AI, machine learning, and life sciences.
Earlier, Richardson spent more than eight years as an Executive Director in J.P. Morgan’s global healthcare investment banking team, advising on equity and debt financings and more than 25 cross-border M&A transactions with an aggregate value exceeding $100 billion. He was also a member of the founding team at Quantitative Insights, which received FDA approval for a machine-learning system designed for breast cancer diagnosis.
Richardson currently serves as a Non-Executive Director at Autolus Therapeutics and Linden Lake Labs. Engitix expects his experience in biotechnology strategy, capital markets, AI, and corporate development to support the company as it moves closer to becoming a clinical-stage biotechnology business.
KEY QUOTES:
“We are delighted to welcome Ryan to the Engitix Board at such an important stage in our development. His experience across biotechnology strategy, capital markets, corporate development and AI will be highly valuable as we advance our proprietary pipeline, expand our partnerships and leverage our data and AI capabilities. We are building Engitix to become a leading biotechnology company at the forefront of ECM-based drug discovery and development, and I am delighted to have Ryan joining us for this next phase of our journey.”
Giuseppe Mazza, Co-Founder And CEO Of Engitix
“Engitix is at an inflection point as it advances towards becoming a clinical-stage biotechnology company. I believe the Company’s multi-faceted approach has tremendous potential through its unique ability to unlock deep insights into ECM biology, multi-omics datasets and AI platform, and novel pipeline of potentially transformative therapies in areas of high unmet need. I look forward to working with Giuseppe, the Board, and the wider team as Engitix enters its next phase of growth.”
Ryan Richardson, Independent Non-Executive Director Of Engitix
